NYSE · LLY
Eli Lilly and Company
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
Loading market information…
NASDAQ · DTIL · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Precision BioSciences, Inc.’s quoted price sits in the upper half of its reported 52-week range, 22.66% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Precision BioSciences, Inc.’s next earnings report is currently expected on Nov 2, 2026, with estimated earnings per share of -$0.85. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Precision BioSciences, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Precision BioSciences, Inc. is a clinical-stage biotechnology firm based in the United States, specializing in the creation of both in vivo gene editing solutions and ex vivo allogeneic CAR T-cell therapies. At its core is ARCUS, a proprietary genome editing platform designed to address and potentially cure genetic diseases. The company's portfolio also encompasses Ex vivo Allogeneic CAR T Immunotherapy, an innovative approach where specific immune cells, known as T-cells, are genetically modified outside the body to precisely identify and eliminate cancer cells. Among its prominent therapeutic candidates are: PBCAR0191, currently undergoing Phase 1/2a clinical trials for adult patients battling relapsed/refractory (R/R) non-Hodgkin lymphoma or R/R B-cell precursor acute lymphoblastic leukemia (B-ALL). PBCAR19B, an anti-CD19 CAR T candidate leveraging a "stealth cell" platform through a single-step gene edit, engineered to reduce the likelihood of chromosomal abnormalities. PBCAR269A, an investigational allogeneic CAR T immunotherapy formulated to target BCMA, intended for the treatment of R/R multiple myeloma. Precision BioSciences has strategically formed several collaborative alliances. These include an agreement with Les Laboratoires Servier for the development and commercialization of allogeneic chimeric antigen receptor T-cell therapies, aimed at various antigen targets, including hematological cancers beyond CD19, and solid tumors. The company is also partnering with Tiziana Life Sciences to assess foralumab, a fully human anti-CD3 monoclonal antibody, for its utility as a lymphodepleting agent in potential cancer treatments. Furthermore, a collaboration with iECURE, Inc. focuses on advancing ARCUS-based gene editing therapies. Established in 2006, Precision BioSciences, Inc. maintains its corporate headquarters in Durham, North Carolina.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:54 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 15, 2025 | -$2.21-413.95% vs estimate | $29.00K-99.54% vs estimate |
|---|
| Q4 2024 | Mar 26, 2025 | -$3.20-53.11% vs estimate | $638.00K-93.62% vs estimate |
|---|
| Q3 2024 | Nov 4, 2024 | -$2.83-258.23% vs estimate | $576.00K-86.53% vs estimate |
|---|
THE ANALYST VIEW
12 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 1 contributors · Median target $20.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
$8.87-$0.19 (-2.1%)
Q32 Bio Inc.’s quoted price sits in the lower half of its reported 52-week range, 62.37% below the high.
$2.24-$0.01 (-0.44%)
Alector, Inc.’s quoted price sits in the upper half of its reported 52-week range, 18.84% below the high.
$2.29-$0.09 (-3.78%)
Acumen Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 36.39% below the high.
$8.26-$0.14 (-1.67%)
Atrium Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 50.75% below the high.
$10.69$0.00 (0.0%)
Gossamer Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 96.55% below the high.
$0.29-$0.01 (-4.69%)
Heron Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 81.37% below the high.
$1.15$0.00 (0.0%)
HOOKIPA Pharma Inc.’s quoted price sits in the lower half of its reported 52-week range, 25.81% below the high.
